SEARCH

SEARCH BY CITATION

References

  • 1
    Arroyo V, Rodés J. A rational approach to the treatment of ascites. Postgrad Med J 1975; 51: 558562.
  • 2
    Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathological characteristics. Am J Med 1965; 39: 184198.
  • 3
    Papper S, Saxon L. The diuretic response to administered water in patients with liver disease. II. Laennec's cirrhosis of the liver. Arch Intern Med 1959; 103: 750760.
  • 4
    Arroyo V, Bosch J, Gaya-Beltrán J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94: 198201.
  • 5
    Arroyo V, Ginès P, Rimola A, et al. Renal function abnormalities, prostaglandins and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81 (Suppl 2): 102122.
  • 6
    Needleman P, Greenwald JE. Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte and blood-pressure homeostasis. N Engl J Med 1986; 314: 828834.
  • 7
    Editorial—Atrial natriuretic peptide. Lancet 1986; 2: 371372.
  • 8
    Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 1985; 313: 13301340.
  • 9
    De Bold AJ. Atrial natriuretic factor: an overview. Fed Proc 1986; 45: 20812085.
  • 10
    Kimura T, Abe K, Ota K, et al. Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endocrinol Metab 1986; 62: 10031010.
  • 11
    Anderson JV, Donckier J, MacKenna WS, et al. The plasma release of atrial natriuretic pepti de in man. Clin Sci 1986; 71: 151155.
  • 12
    Ackermann V. Structure and function of atrial natriuretic peptides. Clin Chem 1986; 32: 241247.
  • 13
    Manning PT, Schwartz D, Katsube NC, et al. Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985; 229: 395397.
  • 14
    Pérez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Intern 1984; 26: 7280.
  • 15
    Ganz W, Tamura K, Marcus HS, et al. Measurement of coronary sinus blood flow by continuous thermodilution. Circulation 1971; 44: 181195.
  • 16
    Lang RE, Dietz R, Merkel A, et al. Plasma atrial natriuretic peptide values in cardiac disease. J Hypertension 1986; 4 (Suppl 2): S119S123.
  • 17
    Espiner EA, Nicholls MG, Yandle TG, et al. Studies on the secretion, metabolism and action of atrial natriuretic pepti de in man. J Hypertension 1986; 4 (Suppl 2): S85S91.
  • 18
    Crozier IG, Nicholls MG, Ikram H, et al. Atrial natriuretic peptide in humans. Production and clearance by various tissues. Hypertension 1986; 8 (Suppl II): II 11II 15.
  • 19
    Bates ER, Shenker Y, Grekin RJ. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation 1986; 73: 11551161.
  • 20
    Bürgisser E, Raine AEG, Erne P, et al. Human cardiac plasma concentrations of atrial natriuretic peptide quantified by radioreceptor assay. Biochem Biophys Res Commun 1985; 133: 12011209.
  • 21
    Bosch J, Mastai R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 12001205.
  • 22
    Betriu A, Castañer A, Sanz G, et al. Angiographic findings one month after myocardial infarction. A prospective study of 259 survivors. Circulation 1982; 62: 10991105.
  • 23
    Arendt RM, Gerbes AL, Ritter D, et al. Atrial natriuretic factor in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver. J Hypertension 1986; 4 (Suppl 2): S131S135.
  • 24
    Brabant G, Jüppner H, Kirschner M, et al. Human atrial natriuretic peptide (ANP) for the treatment of patients with liver cirrhosis and ascites. Klin Wochenschr 1986; 64 (Suppl VI): 108111.
  • 25
    Morgan T, Imada T, Inagami T. Atrial natriuretic protein (ANP) in the hepatorenal syndrome (HRS) (Abstract). Hepatology 1986; 6: 1215.
  • 26
    Burghardt W, Wernze H, Diehl KL. Atrial natriuretic peptide in hepatic cirrhosis: relation to stage of disease, sympathoadrenal system and renin-aldosterone axis. Klin Wochenschr 1986; 64 (Suppl VI): 103107.
  • 27
    Shenker Y, Sider RS, Ostafin EA, et al. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 1985; 76: 16841687.
  • 28
    Henriksen JH, Schütten HJ, Bendtsen F, et al. Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. Liver 1986; 6: 361368.
  • 29
    Gerbes AL, Arendt RM, Riedel A, et al. Rote of atrial natriuretic factor (ANF) in volume regulation of healthy and cirrhotic subjects: effects of water immersion (Abstract). Gastroenterology 1986; 90: 1727.
  • 30
    Bonkovsky H, Hartle D, Simon D, et al. Decreased plasma atrial natriuretic peptides in cirrhotic ascitic patients (Abstract). Hepatology 1986; 6: 1213.
  • 31
    Sagnella GA, Markandu ND, Shore AC, et al. Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet 1985; 2: 12081211.
  • 32
    Weidmann P, Hellmueller B, Vehlinger DE, et al. Plasma levels and cardiovascular, endocrine and excretory effects of atrial natriuretic peptide during different sodium intakes in man. J Clin Endocrino. Metab 1986; 62: 10271036.
  • 33
    Epstein M, Loutzenhiser RD, Friedland E, et al. Increases in circulating atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. J Hypertension 1986; 4 (Suppl 2): S93S99.
  • 34
    Sugawara A, Nakao K, Morii N, et al. α-Human atrial natriuretic polypeptide is released from the heart and circulates in the body. Biochem Biophys Res Commun 1985; 129: 439446.
  • 35
    Kouz S, Gosselin G, Bourassa MG, et al. Very high concentrations of immunoreactive atrial natriuretic factor (ir-ANF) in the human coronary sinus (Abstract). J Am Coll Cardiol 1986; 7: 70A.
  • 36
    Cohn JN, Khatri JM, Groszmann R, et al. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique. Am J Med 1972; 53: 704714.
  • 37
    Groszmann R, Kotelanski B, Cohn JN, et al. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med 1972; 53: 715722.
  • 38
    Vorobioff J, Bredfeldt JE, Groszmann R. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87: 11201126.
  • 39
    Arroyo V, Bosch J, Mauri M, et al. Effect of angiotensin-II blockade on systemic and hepatic hemodynamics and on renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11: 221229.
  • 40
    Reynolds TB, Mikkelsen WP, Redeker AG, et al. The effect of a side to side portacaval shunt on hepatic hemodynamics in cirrhosis. J Clin Invest 1962; 41: 12421248.
  • 41
    Kotelanski B, Groszmann RJ, Cohn JN. Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 1972; 63: 102111.
  • 42
    Jiménez W, Martínez-Pardo A, Arroyo V, et al. Atrial natriuretic factor: reduced cardiac content in cirrhotic rats with ascites. Am J Physiol 1986; 19: F749F752.
  • 43
    Kohno M, Takaori K, Matsuura T, et al. Atrial natriuretic polypeptide in atria and plasma in experimental hyperthyroidism and hypothyroidism. Biochem Biophys Res Commun 1986; 134: 178183.
  • 44
    Edwards BS, Ackermann DM, Schwab TR, et al. The relationship between atrial granularity and circulating atrial natriuretic peptide in hamsters with congestive heart failure. Mayo Clin Proc 1986; 61: 517521.
  • 45
    Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 9299.